Advertisement

Biologic and oral therapies in development for the treatment of psoriasis

  • Maria R. Robinson
  • Neil J. Korman
Part of the Milestones in Drug Therapy book series (MDT)

Abstract

Over the last several years, tremendous advances have been made in understanding the pathogenesis of psoriasis. These new insights have provided the framework for the development of several new classes of targeted therapies, including monoclonal antibodies and fusion proteins. Several of these drugs, including those targeting tumor necrosis factor and T cell activation, appear to be safe and effective over the short-term for the treatment of patients with psoriasis. As more is learned about the pathogenesis of psoriasis, novel therapeutic targets will be identified. It is the hope that these discoveries will continually develop into new therapies thus providing patients with psoriasis more effective treatment options. Here, we will briefly review new psoriasis therapies which are currently in development.

Keywords

Calcineurin Inhibitor Fumaric Acid Plaque Psoriasis Certolizumab Pegol Severe Psoriasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ho VC (2004) The use of ciclosporin in psoriasis: a clinical review. Br J Dermatol 150: 1–10PubMedCrossRefGoogle Scholar
  2. 2.
    Bissonnette R, Papp K, Poulin Y, Lauzon G, Aspeslet L, Huizinga R, Mayo P, Foster RT, Yatscoff RW, Maksymowych WP (2006) A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis. J Am Acad Dermatol 54: 472–478PubMedCrossRefGoogle Scholar
  3. 3.
    Aspeslet L, Freitag D, Trepanier D, Abel M, Naicker S, Kneteman N, Foster R, Yatscoff R (2001) ISATX247: a novel calcineurin inhibitor. Transplantation Proceedings 33: 1048–1051PubMedCrossRefGoogle Scholar
  4. 4.
    Birsan T, Dambrin C, Freitag DG, Yatscoff RW, Morris RE (2005) The novel calcineurin inhibitor ISA247: a more potent immunosuppressant than cyclosporine in vitro. Transpl Int 17: 767–771PubMedCrossRefGoogle Scholar
  5. 5.
    Stalder M, Birsan T, Hubble RW, Paniagua RT, Morris RE (2003) In vivo evaluation of the novel calcineurin inhibitor ISATX247 non-human primates. J Heart Lung Transplant 22: 1343–1352PubMedCrossRefGoogle Scholar
  6. 6.
    Gregory CR, Kyles AE, Bernsteen L, Wagner GS, Tarantal AF, Christe KL, Brignolo L, Spinner A, Griffey SM, Paniagua RT et al. (2004) Compared with cyclosporine, ISATX247 significantly prolongs renal-allograft survival in a nonhuman primate model. Transplantation 78: 681–685PubMedCrossRefGoogle Scholar
  7. 7.
    Nugteren-Huying WM, van der Schroeff JG, Hermans J, Suurmond D (1990) Fumaric acid therapy for psoriasis: a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 22: 311–312PubMedGoogle Scholar
  8. 8.
    Altmeyer PJ, Matthes U, Pawlak F, Hoffmann K, Frosch PJ, Ruppert P, Wassilew SW, Horn T, Kreysel HW, Lutz G et al. (1994) Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 30: 977–981PubMedCrossRefGoogle Scholar
  9. 9.
    Ormerod AD, Mrowietz U (2004) Fumaric acid esters, their place in the treatment of psoriasis. Br J Dermatol 150: 630–632PubMedCrossRefGoogle Scholar
  10. 10.
    Mrowietz U, Christophers E, Altmeyer P (1999) Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. Br J Dermatol 141: 424–429PubMedCrossRefGoogle Scholar
  11. 11.
    Treumer F, Zhu K, Glaser R, Mrowietz U (2003) Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol 121: 1383–1388PubMedCrossRefGoogle Scholar
  12. 12.
    (2005) BG 12: BG 00012, BG 12/Oral Fumarate, FAG-201, second-generation fumarate derivative — Fumapharm/Biogen Idec. Drugs R D 6: 229–230Google Scholar
  13. 13.
    Mrowietz U, Reich K, Spellman MC (2006) Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: results of a phase 3 study. J Am Acad Derm 54, no 3, Supp Mar 2006: AB202, P2816Google Scholar
  14. 14.
    Khobzaoui M, Gutke HJ, Burnet M (2005) CC-10004. Curr Opin Invst Drugs 6: 518–525Google Scholar
  15. 15.
    Gottlieb AB, Malaviya R, Rohane P, Jones M (2006) Biological activity of CC-10004 with severe plaque-type psoriasis. J Am Acad Dermatol 54, no 3, Supp Mar 2006: AB9, P34Google Scholar
  16. 16.
    Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, Heffernan M, Miller B, Hamlin R, Lim L et al. (2006) Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Derm 55: 598–606PubMedCrossRefGoogle Scholar
  17. 17.
    Kaushik VV, Moots RJ (2005) CDP-870 (certolizumab) in rheumatoid arthritis. Expert Opin Biol Ther 5: 601–606PubMedCrossRefGoogle Scholar
  18. 18.
    Choy EH, Hazleman B, Smith M, Moss K, Lisi L, Scott DG, Patel J, Sopwith M, Isenberg DA (2002) Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology 41: 1133–1137PubMedCrossRefGoogle Scholar
  19. 19.
    Winter TA, Wright J, Ghosh S, Jahnsens J, Innes A, Round P (2004) Intravenous CDP870, a PEGylated Fab_ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn’s disease: an exploratory study. Aliment Pharmacol Ther 20: 1337–1346PubMedCrossRefGoogle Scholar
  20. 20.
    Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, Bernstein CN, Staun M, Thomsen O, Innes A (2005) A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology 129: 807–818PubMedCrossRefGoogle Scholar
  21. 21.
    Ortonne JP, Sterry W, Tasset C, Reich K (2007) Efficacy and safety of subcutaneous certolizumab pegol, the first PEGylated anti-TNFa, in patients with moderate-to-severe chronic plaque psoriasis: preliminary results from a double-blind, placebo-controlled trial. J Am Acad Derm 56,Supp2, Feb 2007: AB6, P21Google Scholar
  22. 22.
    Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q et al. (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6: 1133–1141PubMedCrossRefGoogle Scholar
  23. 23.
    Yawalkar N, Karlen S, Hunger R, Brand CU, Braathen LR (1998) Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol 111: 1053–1057PubMedCrossRefGoogle Scholar
  24. 24.
    Kauffman CL, Aria N, Toichi E, McCormick TS, Cooper KD, Gottlieb AB, Everitt DE, Frederick B, Zhu Y, Graham MA et al. (2004) A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 123: 1037–1044PubMedCrossRefGoogle Scholar
  25. 25.
    Gottlieb A, Frederick B, Everitt D, McCormick T (2005) A phase 1 study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 P40 antibody administered subcutaneously in subjects with plaque psoriasis. J Am Acad Dermato 52, part 2, No 3: p.172, p.2705Google Scholar
  26. 26.
    Krueger GG, Langely RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley LT, Lebwohl M (2007) A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356: 580–592PubMedCrossRefGoogle Scholar
  27. 27.
    Gottlieb A, Cather J, Hamilton T, Sherman M (2006) Preliminary clinical safety and efficacy results from an open-label phase 2 study of STA-5326, an oral IL-12/IL-23 inhibitor, in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 54, Suppl no3, Mar 2006: AB10, p.37CrossRefGoogle Scholar
  28. 28.
    Gottlieb AB, Kang S, Linden KG, Lebwohl M, Menter A, Abdulghani AA, Goldfarb M, Chieffo N, Totoritis MC (2004) Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis. Clin Immunolog 111: 28–37CrossRefGoogle Scholar
  29. 29.
    Gottlieb AB, Lebwohl M, Totoritis MC, Abdulghani AA, Sheuy SR, Romano P, Chaudhari U, Allen RS, Lizambri RG (2002) Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody. J Am Acad Dermatol 47: 692–700PubMedCrossRefGoogle Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2008

Authors and Affiliations

  • Maria R. Robinson
    • 1
  • Neil J. Korman
    • 1
  1. 1.Department of Dermatology, Murdough Family Center for PsoriasisUniversity Hospitals Case Medical CenterClevelandUSA

Personalised recommendations